

Figure S1. **T cell and B cell landscapes in LLNs from ILD patients compared with matched controls.** (**A**) Box plots comparing the median fluorescence intensity of individual T cell markers based on all samples in batches 1-3. Fold change was calculated relative to the mean values of control samples, separately for each batch. (**B**) Representative UMAP of T cells. Each group (control vs ILD) contains 130,000 T cells concatenated from 13 individuals (10,000 cells per individual) in batch 1. (**C**) Fluorescence intensity of each T cell parameter overlaid on the UMAP plot. (**D**) Box plots comparing the median fluorescence intensity of individual B cell markers based on all samples in batches 1-3. Fold change was calculated relative to the mean values of control samples, separately for each batch. (**E**) Representative UMAP of B cells. Each group (control vs ILD) contains 130,000 B cells concatenated from 13 individuals (10,000 cells per individual) in batch 1. (**F**) Fluorescence intensity of each B cell parameter overlaid on the UMAP plot.



Figure S2. **T cell subpopulations in LLNs from ILD patients compared with matched controls.** (A) Comparison of CD4 T cell frequencies in control and ILD LLNs. (B) Comparison of CD8 T cell frequencies in control and ILD LLNs. **c.** Comparison of CD4 to CD8 T cell ratio in control and ILD LLNs. (**D-F**) PCA of CD8 T cells based on fluorescence intensities of 15 parameters: CD154, HLA-DR, CCR7, CD25, ICOS, CD127, GATA3, V $\alpha$ 7.2, PBS-57 loaded CD1d tetramer, V $\delta$ , PD1, ROR $\gamma$ t, CD38, CD45RA and CD137. An analysis was run with 1,600 cells, 669 cells, and 1,100 cells for batch1, batch2, and batch 3, respectively. (**G-H**) Box plots comparing the median fluorescence intensity of individual CD8 T cell markers based on all samples in batches 1-3. **i.** Box plots comparing the median fluorescence intensity of individual Tcon markers based on all samples in batches 1-3. **j.** Box plots comparing the median fluorescence intensity of individual Treg markers based on all samples in batches 1-3. **j.** Box plots comparing the median fluorescence intensity of individual Treg markers based on all samples, separately for each batch. Parameters that are significantly associated with ILD based on a likelihood-ratio test on each logistic regression coefficient are shown. P-values were adjusted by Benjamini-Hochberg correction. P<0.05 (\*), P<0.01 (\*\*), P<0.001 (\*\*\*), P<0.0001 (\*\*\*\*).



Figure S3. Gating strategies for T cell populations.



Figure S4. Gating strategies for B cell populations.



Figure S5. **Heatmap with unsupervised clustering based on immune cell abundance.** Heatmap visualization of a hierarchical clustering of control and ILD individuals based on z-scored frequencies of 39 immune cell populations.

Mixed-effects ML regression				Number of	obs	=	274
Group variable:			Number of	groups	=	31	
				Obs per a	roup:		
					min	n =	2
					avg	g =	8.8
					max	x =	37
				Wald chi2	(3)	=	54.83
Log likelihood =	-972.3637			Prob > ch	i2	=	0.0000
fvc	Coef.	Std. Err.	z	P> z	[95%	Conf	. Interval]
year	-1.453615	.3754472	-3.87	0.000	-2.189	9479	7177524
GCB_status	6.396411	5.580307	1.15	0.252	-4.54	4079	17.33361
GCB∗year	-1.99864	.6660458	-3.00	0.003	-3.304	4066	6932146
_cons	55.72422	3.998668	13.94	0.000	47.88	B697	63.56146
Random-effects Parameters		Estimate	Std	. Err.	[95% Co	onf. :	Interval]
mrn: Identity		+ 					
	<pre>var(_cons)</pre>	224.9574	59.4	48363	133.975	51	377.7257
var(Residual)		47.42213	4.303841		39.6944	41	56.65427
LR test vs. line	ar model: chi	bar2(01) = 34	40.84	Pro	b >= ch:	ibar2	= 0.0000

Figure S6. **Relationship between the lung function changes over time and GC B cell status in explanted LLNs.** Mixed-effects regression modeling with a random intercept was used to analyze changes in forced vital capacity (FVC) over time (year) by germinal center B cell status (GCB\_status) in explanted LLNs.



Figure S7. Longitudinal analysis of autoantibody amounts in ILD plasma. (A-O) Autoantibody signals based on PhIP-seq results (RPK: reads per 100k) were compared between longitudinally paired plasma samples from ILD patients (n=51). Intervals between the first and later time-points range between 98 to 2952 days. Paired Wilcoxon p-values are displayed for each of the 15 ILD antigens.



## Figure S8. Immunofluorescence analysis of ABLIM1 in control lungs. Representative

immunofluorescence staining of organ donor control lungs for Hoechst, alpha-smooth muscle actin ( $\alpha$ -SMA), cytokeratin 17 (KRT-17), and ABLIM1. Images were taken with a 40x objective, and the scale bar is 100um.

Isoform a	1 MPAFLGLKCLGKLCSSEKSKVTSSERTSARGSNRKRLIVEDRRVSGTSFTAHRRATITHLLYLCPKDYCPRGRV 74					
Isoiorm j						
Epitope (n=3)	MLAL POPULOZ POPUL					
Epicope (N=1)	ERISARGSNKKKLIVEDKKVSGISFIAHKKAIIIHLLILOPKDIOPKGK-					
Isoform a	440 QDVRDRMIHRSTSQGSINSPVYSRHSYTPTTSRSPQHFH					
Isoform j	124 QDVRDRMIHRSTSQGSINSPVYSRHSYTPTTSRSPQHFH					
Epitope (n=1)	-DVRDRMIHRSTSQGSINSPVYSRHSYTPTTSRSPQHFHRPDQGINIYRK					
Isoform a	GNEPSSGRNSPLPYRPDSRPLTPTYAQAPKHFHVPDQGINIYRKPPIYKQH 531					
Isoform j	168 SPGVQRLSYLRTSSLSPTHSDSRPN <mark>PPFRHHFIPHIKGNEPSSGRNSPLP</mark> YRPDSRPLTPTYAQAPKHFHVPDQGINIYRKPPIYKQH 255					
Epitope (n=5)	-PGVQRLSYLRTSSLSPTHSDSRPN <mark>PPFRHHF1PH1KGNEPSSGRNSPLP</mark>					
Epitope (n=5)	PTHSDSRPN <mark>PPFRHHF1PH1KGNEPSSGRNSPLP</mark> YRPDSRPLTPTYAQA					
Epitope (n=2)	PPFRHHF1PH1KGNEPSSGRNSPLPYRPDSRPLTPTYAQAPKHFHVPDQ					
Epitope (n=1)	NSPLPYRPDSRPLTPTYAQAPKHFHVPDQGINIYRKPPIYKQH					
Isoform a	522 YRKPPIYKQH()RRSSGREEDDEELLRRRQLQEEQLMKLNSGLGQLILKEEMEKESRERSS 632					
Isoform j	246 YRKPPIYKQHGPDMKRRSSGREEDDEELLRRRQLQEEQLMKLNSGLGQLILKEEMEKESRERSS 309					
Epitope (n=2)	KPPIYKQHGPDMKRRSSGREEDDEELLRRRQLQEEQLMKLNSGLGQLIL					
Epitope (n=1)	KRRSSGREEDDEELLRRRQLQEEQLMKLNSGLGQLILKEEMEKESRERS-					
Isoform a	675 YNSYGDVSGGVRDYQTLPDGHMPAMRMDRGVSMPNMLEPKIFPYEMLMVTN 725					
Isoform j	352 YNSYGDVSGGVRDYQTLPDGHMPAMRMDRGVSMPNMLEPKIFPYEMLMVTN 402					
Epitope (n=1)	-NSYGDVSGGVRDYQTLPDGHMPAMRMDRGVSMPNMLEPKIFPYEMLMVT-					

Figure S9. **Immunodominant peptide epitopes on ABLIM1.** Phage-displayed library sequences (epitope sequences) that were immunoprecipitated by ILD patient plasma antibodies were aligned to ABLIM1 isoform a (NP\_002304) and isoform j (NP001309817). Number of patients that had reactivity to each epitope sequence is indicated on the figure. Highlighted region indicates the proline-rich region, which is commonly represented in a total of 12 phage-immunoprecipitated sequencing hits.